Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicentre, Interventional Treatment, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Two Different Doses of Nefecon in Primary IgA Nephropathy Patients at Risk of End-stage Renal Disease

Trial Profile

A Multicentre, Interventional Treatment, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Two Different Doses of Nefecon in Primary IgA Nephropathy Patients at Risk of End-stage Renal Disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 01 Oct 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Budesonide (Primary)
  • Indications IgA nephropathy
  • Focus Therapeutic Use
  • Acronyms NEFIGAN
  • Sponsors Calliditas Therapeutics; Pharmalink AB
  • Most Recent Events

    • 01 Oct 2018 According to a Calliditas Therapeutics media release, extended post-hoc results from this trial were presented at the International IgA Nephropathy Network meeting (IIgANN; Buenos Aires; Argentina; 28 Sep 2018.).All abstracts and summaries of the sessions are published in a special number of the scientific journal Kidney Diseases.
    • 01 Oct 2018 Extended post-hoc results from this trial, presented in a Calliditas Therapeutics media release.
    • 25 Sep 2018 According to a Calliditas Therapeutics AB media release, post-hoc results from this trial will be presented in an oral session at the International IgA Nephropathy Network Meeting (IIgANN).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top